补肾强骨方联合化疗治疗多发性骨髓瘤15例疗效观察  

Therapeutic Effect of Bushen Qianggu Prescription Combined with Chemotherapy for Multiple Myeloma:A Report of 15 Cases

作　　者：黄智莉[1] 于天启[1] 戴微[1] 杨宏光[1] 陈亚勇[1] 陈志雄[1] 

机构地区：[1]广州市中医医院血液科,广东广州510130

出　　处：《新中医》2010年第1期49-51,共3页New Chinese Medicine

摘　　要：目的:观察自拟补肾强骨方联合化疗治疗多发性骨髓瘤的临床疗效。方法:对15例多发性骨髓瘤患者采用自拟补肾强骨方联合化疗治疗,21～28天为1周期,6周期后评定疗效。停药后随访18月。结果:总有效率为86.67%。治疗前后血红蛋白、M蛋白、浆细胞比例、血β_2微球蛋白(β_2-MG)、乳酸脱氢酶(LDH)、C-反应蛋白(CRP)比较,差异均有非常显著性意义(P<0.01);治疗前后血钙比较,差异有显著性意义(P<0.05)。不良反应大部分为Ⅰ～Ⅱ级,经对症处理后均可坚持用药。随访18月,生存率达到80.0%,生活质量提高8例,稳定4例,降低3例。结论:补肾强骨方联合化疗治疗多发性骨髓瘤,可明显提高患者生活质量,降低复发率,使患者病情相对稳定。Objective:To observe the therapeutic effect of Bushen Qianggu Prescription (BQP) combined with chemotherapy for multiple myeloma(MM).Methods: Fifteen MM patients received BQP combined with chemotherapy.One treatment period lasted 21～28 days,and the therapeutic effect was evaluated after 6 treatment periods.A follow-up of 18 months was also carried out.Results:The total effective rate was 86.67%.After treatment,the difference of serum levels of hemoglobin,M protein,plasma cells,microglobulin(β2-MG),lactate dehycrogenase(LDH),and C-reactive protein(CRP) in patients were significant before and after treatment(P<0.01).Blood calcium was also improved(P<0.05).The side effects ranged in stageⅠ-Ⅱ,and can be relieved after symptomatic treatment.The results of 18- month follow-up showed that the survival rate was up to 80.0%,and the life of quality was improved in 8 patients,stabilized in 4 and decreased in 3.Conclusion: BQP combined with chemotherapy can improve the life of quality,decrease recurrence rate and relieve the symptoms and signs in patients with multiple myeloma.

关 键 词：多发性骨髓瘤 中西医结合疗法 补肾强骨方 化学疗法 

分 类 号：R733.3[医药卫生—肿瘤]